Literature DB >> 2446865

Inhibition of SV40 replicon function by engineered antisense RNA transcribed by RNA polymerase III.

P A Jennings1, P L Molloy.   

Abstract

Promoters recognized by RNA polymerase III were used to direct synthesis of RNAs of opposite polarity to the 5' end of the mRNA for the large T-antigen of SV40. A construct was made utilizing the adenovirus (human type II) VA1 gene promoter linked to 163 bp of SV40 DNA sequences cloned in antisense orientation relative to the promoter. The SV40 sequence corresponds to the 5' end of the large T-antigen gene. In addition to the antisense constructs control plasmids were utilized which either lacked both promoter and SV40 elements, lacked RNA polymerase III promoter elements but contained SV40 sequences or contained the VA1 gene promoter fused to SV40 sequences in the sense orientation. The function of the various gene fusions was demonstrated in an in vitro transcription system and in vivo by S1 nuclease 5' end mapping following transfection into COS1 cells. Cotransfection of COS1 cells with the 'antisense' gene and a plasmid containing an SV40 origin of replication resulted in a substantial transient inhibition of SV40-replicon function when compared to control determinations (50% to nearly complete inhibition of large T-antigen dependent DNA replication for 18-36 h). These results show that an antisense RNA generated by RNA polymerase III can effectively block expression of a chromosomally located gene.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446865      PMCID: PMC553741          DOI: 10.1002/j.1460-2075.1987.tb02610.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  27 in total

1.  Complete nucleotide sequence of SV40 DNA.

Authors:  W Fiers; R Contreras; G Haegemann; R Rogiers; A Van de Voorde; H Van Heuverswyn; J Van Herreweghe; G Volckaert; M Ysebaert
Journal:  Nature       Date:  1978-05-11       Impact factor: 49.962

2.  SV40-transformed simian cells support the replication of early SV40 mutants.

Authors:  Y Gluzman
Journal:  Cell       Date:  1981-01       Impact factor: 41.582

Review 3.  Transcription by RNA polymerase III.

Authors:  G Ciliberto; L Castagnoli; R Cortese
Journal:  Curr Top Dev Biol       Date:  1983       Impact factor: 4.897

4.  Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis.

Authors:  J G Izant; H Weintraub
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

5.  Translational control of IS10 transposition.

Authors:  R W Simons; N Kleckner
Journal:  Cell       Date:  1983-09       Impact factor: 41.582

6.  Co-existence of vinculin and a vinculin-like protein of higher molecular weight in smooth muscle.

Authors:  J R Feramisco; J E Smart; K Burridge; D M Helfman; G P Thomas
Journal:  J Biol Chem       Date:  1982-09-25       Impact factor: 5.157

7.  Transcription maps of adenovirus.

Authors:  P A Sharp; A J Berk; S M Berget
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

8.  Synthesis in vitro of an exceptionally long RNA transcript promoted by an AluI sequence.

Authors:  J L Manley; M T Colozzo
Journal:  Nature       Date:  1982-11-25       Impact factor: 49.962

9.  The alpha protein ICP0 does not appear to play a major role in the regulation of herpes simplex virus gene expression during infection in tissue culture.

Authors:  R M Sandri-Goldin; R E Sekulovich; K Leary
Journal:  Nucleic Acids Res       Date:  1987-02-11       Impact factor: 16.971

10.  Faithful transcription of eukaryotic genes by RNA polymerase III in systems reconstituted with purified DNA templates.

Authors:  P A Weil; J Segall; B Harris; S Y Ng; R G Roeder
Journal:  J Biol Chem       Date:  1979-07-10       Impact factor: 5.157

View more
  15 in total

Review 1.  RNA interference: from an ancient mechanism to a state of the art therapeutic application?

Authors:  Christoph Arenz; Ute Schepers
Journal:  Naturwissenschaften       Date:  2003-07-23

2.  Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes.

Authors:  Jonghoe Byun; Ning Lan; Meredith Long; Bruce A Sullenger
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

3.  Inhibition of gene expression by a short sense fragment.

Authors:  F H Cameron; P A Jennings
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

4.  Inhibition of SV40 gene expression by microinjected small antisense RNA and DNA molecules.

Authors:  M Graessmann; G Michaels; B Berg; A Graessmann
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

5.  Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III.

Authors:  S Koseki; T Tanabe; K Tani; S Asano; T Shioda; Y Nagai; T Shimada; J Ohkawa; K Taira
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

6.  Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter.

Authors:  J D Thompson; D F Ayers; T A Malmstrom; T L McKenzie; L Ganousis; B M Chowrira; L Couture; D T Stinchcomb
Journal:  Nucleic Acids Res       Date:  1995-06-25       Impact factor: 16.971

7.  Inhibition of fatty acid synthesis by expression of an acetyl-CoA carboxylase-specific ribozyme gene.

Authors:  J Ha; K H Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

8.  Specific gene suppression by engineered ribozymes in monkey cells.

Authors:  F H Cameron; P A Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.

Authors:  P K Liu; E Kraus; T A Wu; L C Strong; M A Tainsky
Journal:  Oncogene       Date:  1996-06-06       Impact factor: 9.867

10.  A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1.

Authors:  M Yu; J Ojwang; O Yamada; A Hampel; J Rapapport; D Looney; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.